EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Clinical application value of the updated FIGO 2023 classification compared with FIGO 2009 for endometrial cancer staging in a Chinese cohort

Xiaoyan Zhao iD, Lili Sun iD, Fujing Sun iD, Yushui Liu iD, Xin Zhang iD, Yanmei Zhu iD

Journal of Gynecologic Oncology · 2026

DOI: 10.3802/jgo.2026.37.e76 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Xiaoyan Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Affiliated Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital and Institute, Cancer Hospital of C…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Staging. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Liaoning Provincial Natural Science Foundation, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To compare the predictive performance of the International Federation of Gynecology and Obstetrics (FIGO) 2009 and FIGO 2023 staging systems for endometrial cancer (EC) and to assess whether FIGO 2023 system better predicts patient prognosis. METHODS: A retrospective analysis of 640 EC patients was conducted, with staging according to the 2009 and 2023 FIGO systems. Kaplan-Meier survival analysis, hazard ratios (HRs), Harrell's concordance index (C-index), and Akaike's Information Criterion (AIC) were used to assess model performance. RESULTS: A change to a higher substage occurred in 148 patients (23.1%), whereas 12 patients (1.9%) were down-staged, based on the FIGO 2009 staging system. Among early-stage patients, 9 and 62 were reclassified from early-stage (I and II) to IAmPOLEmut and IICmp53abn, respectively, according to the molecular subtypes POLEmut and p53abn, and showed distinctly different prognoses (5-year overall survival [OS]: 100% vs. 75.3%). The 5-year OS and disease-free survival (DFS) rates were better for stage IA3 than for stage IIIA1 (OS: 91.7% vs. 71.6%, DFS: 91.7% vs. 71.3%). Among patients with advanced EC, those with the p53abn molecular subtype had the worst prognoses (5-year OS: 41.6%). Compared to FIGO 2009, FIGO 2023 showed significantly higher HRs for OS and DFS (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsNeoplasm StagingHumansFemaleRetrospective StudiesMiddle AgedPrognosisChinaAgedDisease-Free SurvivalKaplan-Meier EstimateAdultAged, 80 and overEast Asian People

Stichwörter der Autor:innen

Cancer StagingClassificationEndometrial CancerMolecularSurvival

Autor:innen und Institutionen

  • Department of Gynecology, Affiliated Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University), Shenyang, China.
  • Graduate School, Dalian Medical University, Dalian, China.
  • Department of Pathology, Affiliated Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University), Shenyang, China.
  • Department of Gynecology, Affiliated Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University), Shenyang, China. zhangxiangmiao@hotmail.com.
  • Department of Pathology, Affiliated Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University), Shenyang, China. zhuyanmei@cancerhosp-ln-cmu.…

ORCID-Profile: Xiaoyan Zhao, Lili Sun, Fujing Sun, Yushui Liu, Xin Zhang, Yanmei Zhu

Förderung

  • Liaoning Provincial Natural Science Foundation
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Zhao, X., Sun, L., Sun, F., Liu, Y., Zhang, X., & Zhu, Y. (2026). Clinical application value of the updated FIGO 2023 classification compared with FIGO 2009 for endometrial cancer staging in a Chinese cohort. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e76

Vancouver

Zhao X, Sun L, Sun F, Liu Y, Zhang X, Zhu Y. Clinical application value of the updated FIGO 2023 classification compared with FIGO 2009 for endometrial cancer staging in a Chinese cohort. Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e76

BibTeX
@article{Zhao2026,
  author = {Zhao, Xiaoyan and Sun, Lili and Sun, Fujing and Liu, Yushui and Zhang, Xin and Zhu, Yanmei},
  title = {Clinical application value of the updated FIGO 2023 classification compared with FIGO 2009 for endometrial cancer staging in a Chinese cohort},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  doi = {10.3802/jgo.2026.37.e76}
}
Kostenlos starten →